Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C21H27NOS |
| Molecular Weight | 341.51 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](NCCCCC1=CC=CC=C1)[C@@H](O)C2=CC=C3SCCC3=C2
InChI
InChIKey=FJLRGFADCXTJNV-IIBYNOLFSA-N
InChI=1S/C21H27NOS/c1-16(22-13-6-5-9-17-7-3-2-4-8-17)21(23)19-10-11-20-18(15-19)12-14-24-20/h2-4,7-8,10-11,15-16,21-23H,5-6,9,12-14H2,1H3/t16-,21-/m1/s1
| Molecular Formula | C21H27NOS |
| Molecular Weight | 341.51 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Tibalosin is a phenylethylamine derivative patented by Continental Pharma as a potent vasodilator. Tibalosine interacts specifically with alpha- and beta-adrenergic receptors and calcium channel binding sites. In preclinical models, Tibalosin exerts favor influences on arterial pressure in the hypertensive animal. The drug has acceptable toxicity in experimental animals and has been well tolerated by normal human subjects in daily doses of up to 200 mg.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:06:48 GMT 2025
by
admin
on
Mon Mar 31 18:06:48 GMT 2025
|
| Record UNII |
2H3X1M329K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Mon Mar 31 18:06:48 GMT 2025 , Edited by admin on Mon Mar 31 18:06:48 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
76971717
Created by
admin on Mon Mar 31 18:06:48 GMT 2025 , Edited by admin on Mon Mar 31 18:06:48 GMT 2025
|
PRIMARY | |||
|
63996-84-9
Created by
admin on Mon Mar 31 18:06:48 GMT 2025 , Edited by admin on Mon Mar 31 18:06:48 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107043
Created by
admin on Mon Mar 31 18:06:48 GMT 2025 , Edited by admin on Mon Mar 31 18:06:48 GMT 2025
|
PRIMARY | |||
|
5265
Created by
admin on Mon Mar 31 18:06:48 GMT 2025 , Edited by admin on Mon Mar 31 18:06:48 GMT 2025
|
PRIMARY | |||
|
2H3X1M329K
Created by
admin on Mon Mar 31 18:06:48 GMT 2025 , Edited by admin on Mon Mar 31 18:06:48 GMT 2025
|
PRIMARY | |||
|
100000082163
Created by
admin on Mon Mar 31 18:06:48 GMT 2025 , Edited by admin on Mon Mar 31 18:06:48 GMT 2025
|
PRIMARY | |||
|
DTXSID801031652
Created by
admin on Mon Mar 31 18:06:48 GMT 2025 , Edited by admin on Mon Mar 31 18:06:48 GMT 2025
|
PRIMARY | |||
|
C037786
Created by
admin on Mon Mar 31 18:06:48 GMT 2025 , Edited by admin on Mon Mar 31 18:06:48 GMT 2025
|
PRIMARY | |||
|
SUB11017MIG
Created by
admin on Mon Mar 31 18:06:48 GMT 2025 , Edited by admin on Mon Mar 31 18:06:48 GMT 2025
|
PRIMARY | |||
|
C90635
Created by
admin on Mon Mar 31 18:06:48 GMT 2025 , Edited by admin on Mon Mar 31 18:06:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
